285 related articles for article (PubMed ID: 25991590)
1. Comparison of acute renal injury associated with intermittent and extended infusion piperacillin/tazobactam.
McCormick H; Tomaka N; Baggett S; Heierman T; LaFosse J; Gilbert S; Imhof K
Am J Health Syst Pharm; 2015 Jun; 72(11 Suppl 1):S25-30. PubMed ID: 25991590
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Rates of Nephrotoxicity Associated with Vancomycin in Combination with Piperacillin-Tazobactam Administered as an Extended versus Standard Infusion.
Mousavi M; Zapolskaya T; Scipione MR; Louie E; Papadopoulos J; Dubrovskaya Y
Pharmacotherapy; 2017 Mar; 37(3):379-385. PubMed ID: 28079263
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam.
Burgess LD; Drew RH
Pharmacotherapy; 2014 Jul; 34(7):670-6. PubMed ID: 24855041
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Risk Factors of Acute Kidney Injury in Patients Receiving Concomitant Vancomycin and Continuous-Infusion Piperacillin/Tazobactam: A Retrospective Cohort Study.
Blair K; Covington EW
Ann Pharmacother; 2020 Nov; 54(11):1096-1101. PubMed ID: 32406243
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship.
Karino S; Kaye KS; Navalkele B; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Pogue JM
Antimicrob Agents Chemother; 2016 Jun; 60(6):3743-50. PubMed ID: 27067325
[TBL] [Abstract][Full Text] [Related]
6. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
Lodise TP; Lomaestro B; Drusano GL
Clin Infect Dis; 2007 Feb; 44(3):357-63. PubMed ID: 17205441
[TBL] [Abstract][Full Text] [Related]
7. Increased Risk of Acute Kidney Injury in Critically Ill Children Treated With Vancomycin and Piperacillin/Tazobactam.
Holsen MR; Meaney CJ; Hassinger AB; Fusco NM
Pediatr Crit Care Med; 2017 Dec; 18(12):e585-e591. PubMed ID: 28906422
[TBL] [Abstract][Full Text] [Related]
8. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.
Winstead EM; Ratliff PD; Hickson RP; Mueller JE; Judd WR
Int J Clin Pharm; 2016 Oct; 38(5):1087-93. PubMed ID: 27333796
[TBL] [Abstract][Full Text] [Related]
10. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
Yost RJ; Cappelletty DM;
Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
[TBL] [Abstract][Full Text] [Related]
11. Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.
Cotrina-Luque J; Gil-Navarro MV; Acosta-García H; Alfaro-Lara ER; Luque-Márquez R; Beltrán-García M; Bautista-Paloma FJ
Int J Clin Pharm; 2016 Feb; 38(1):70-9. PubMed ID: 26474861
[TBL] [Abstract][Full Text] [Related]
12. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime.
Gomes DM; Smotherman C; Birch A; Dupree L; Della Vecchia BJ; Kraemer DF; Jankowski CA
Pharmacotherapy; 2014 Jul; 34(7):662-9. PubMed ID: 24753221
[TBL] [Abstract][Full Text] [Related]
13. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.
Downes KJ; Cowden C; Laskin BL; Huang YS; Gong W; Bryan M; Fisher BT; Goldstein SL; Zaoutis TE
JAMA Pediatr; 2017 Dec; 171(12):e173219. PubMed ID: 28973124
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes of Extended Versus Intermittent Infusion of Piperacillin/Tazobactam in Critically Ill Patients: A Prospective Clinical Trial.
Fan SY; Shum HP; Cheng WY; Chan YH; Leung SM; Yan WW
Pharmacotherapy; 2017 Jan; 37(1):109-119. PubMed ID: 27888542
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or with meropenem.
Al Yami MS
J Infect Public Health; 2017; 10(6):770-773. PubMed ID: 28209320
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
Grant EM; Kuti JL; Nicolau DP; Nightingale C; Quintiliani R
Pharmacotherapy; 2002 Apr; 22(4):471-83. PubMed ID: 11939682
[TBL] [Abstract][Full Text] [Related]
17. Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime.
Navalkele B; Pogue JM; Karino S; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Koons J; Hussain T; Perry W; Evans R; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Kaye KS
Clin Infect Dis; 2017 Jan; 64(2):116-123. PubMed ID: 27986669
[TBL] [Abstract][Full Text] [Related]
18. Influence of β-Lactam Infusion Strategy on Acute Kidney Injury.
Cotner SE; Rutter WC; Burgess DR; Wallace KL; Martin CA; Burgess DS
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760891
[TBL] [Abstract][Full Text] [Related]
19. Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in adult and pediatric burn patients.
Hundeshagen G; Herndon DN; Capek KD; Branski LK; Voigt CD; Killion EA; Cambiaso-Daniel J; Sljivich M; De Crescenzo A; Mlcak RP; Kinsky MP; Finnerty CC; Norbury WB
Crit Care; 2017 Dec; 21(1):318. PubMed ID: 29262848
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Economic Impact of Empirical Extended-Infusion Piperacillin-Tazobactam in a Community Medical Center.
Brunetti L; Poustchi S; Cunningham D; Toscani M; Nguyen J; Lim J; Ding Y; Nahass RG
Ann Pharmacother; 2015 Jul; 49(7):754-60. PubMed ID: 25855703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
